ATS 2019 Virtual Final Program

P488 Adherence to Guideline-Directed Therapy in the Management of Chronic Obstructive Pulmonary Disease/ J. Woods, A. Leonhardt, J. Sebaaly, Wingate, NC, p.A3300 P489 Before-After Study of Efficacy of Morphine for Dyspnea in Patients with Chronic Obstructive Pulmonary Disease: JORTC-PAL 07/ Y. Matsuda, Y. Inoue, H. Matsumoto, K. Hosoi, K. Kusama, Y. Kohashi, H. Morishita, T. Yamaguchi, M. Nishikawa, Osaka, Japan, p.A3301 P490 Chronic Obstructive Pulmonary Disease Pharmacological Treatment Effectiveness/ A.C.G. Ferreira, L.S. Dias, J.L.R. Silva Junior, M.F. Rabahi, Goiania, Brazil, p.A3302 P491 Investigation of the Proper Use of Steroids During Admissions for Acute Exacerbation of Chronic Obstructive Pulmonary Disease at a Community Teaching Hospital/ W. Grist, Y. Elamir, Y. Patel, J. Matta, L. Alerte, D. Hipolito, A. Dubey, B. Elamir, Jersey City, NJ, p.A3303 P492 Effects of Direct Switching Dual Bronchodilators Between Dry Powder and Soft Mist Inhalers in COPD Patients/ T. Shirai, T. Akamatsu, K. Tamura, T. Masuda, S. Takahashi, Y. Tanaka, Y. Kishimoto, K. Oishi, Y. Endo, M. Saigusa, A. Yamamoto, S. Morita, K. Asada, Shizuoka, Japan, p.A3304 CLINICAL THEMATIC POSTER SESSION B45 COPD: TREATMENT 9:15 a.m. - 4:15 p.m. KBHCCD Area D (Hall F, Level 2) Viewing: Posters will be on display for entire session. Discussion: 11:15-12:00: authors will be present for individual discussion 12:00-1:00: authors will be present for discussion with assigned facilitators. P494 The Unmet Need of Moderate Exacerbations Among Chronic Obstructive Pulmonary Disease (COPD) Patients Who Initiated Inhaled Maintenance Therapy in United Kingdom (UK) General Practice/ L. Sansbury, D.A. Lipson, C. Bains, G. Anley, A. Ismaila, H. Quasny, Collegeville, PA, p.A3305 P495 Predictors of Empiric Treatment in Smokers with Normal Spirometry/ N. Arnold, C.P. Hersh, E.S. Wan, G. Kinney, K. Young, J.E. Hokanson, E.A. Regan, A.P. Comellas, S. Fortis, Iowa City, IA, p.A3306 P496 DT-0111: A Novel Therapeutic Approach for COPD and Chronic Cough/ A. Pelleg, B. Undem, F. Xu, Philadelphia, PA, p.A3307 P497 The Effect of Tiotropium/Olodaterol versus Salmeterol/Fluticasone on Left Ventricular Function and Lung Hyperinflation in Patients with COPD/ F.J. Herth, J.M. Hohlfeld, J. Haas, A. de la Hoz, X. Jin, K.-F. Kreitner, C.F. Vogelmeier, J. Vogel-Claussen, H. Watz, Heidelberg, Germany, p.A3308 P498 InforMing the PAthway of COPD Treatment (IMPACT Study)-Single Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients with COPD: Results Based on an Analysis of the North American Region/ R.A. Wise, G.J. Criner, M.T. Dransfield, M.K. Han, C.E. Jones, S. Lettis, F.J. Martinez, S.J. Pascoe, H. Quasny, D.A. Lipson, Baltimore, MD, p.A3309 P499 Physicians’ Adherence to Gold 2017 Guidelines in the Management of Chronic Obstructive Pulmonary Disease/ H. Irie, S. Chubachi, N. Kameyama, A. Tsutsumi, K. Sakurai, S. Nakayama, H. Miyata, N. Miyahara, N. Minematsu, T. Shiomi, H. Koh, T. Betsuyaku, K. Fukunaga, Tokyo, Japan, p.A3310 P500 Assessment of Patient Experiences with Respimat ® in Everyday Clinical Practice/ C. Taube, A. Valipour, V. Bayer, A. Kondla, A. Marseille, A. Medvedchikov, M. Haaksma-Herczegh, C.M. Zehendner, Essen, Germany, p.A3311 P501 Effect of Insulin Sensitizers on Exacerbations and Hospitalizations in COPD Patients with Diabetes Mellitus/ T. Pelleg, A. Khan, C. Witt, S.K. Nepal, U.F. Sofi, Roanoke, VA, p.A3312 P502 Evaluation of Rescue Medication Use and Medication Adherence in Patients Initiating Umeclidinium/Vilanterol or Tiotropium/Olodaterol Within a Large US Health Insurer Database/ C. Moretz, L.G.S. Bengtson, E. Koep, L. Sharpsten, L. Le, J. Tong, B. Hahn, R. Stanford, M.J. Asmus, R. Ray, Research Triangle Park, NC, p.A3313 P503 Comparative Real-World Effectiveness of Triple Therapy Versus Dual Bronchodilation on Lung Function Decline in Frequently Exacerbating Patients with COPD/ J. Voorham, M. Kerkhof, G. Georges, S. Vezzoli, A. Papi, C. Vogelmeier, D. Singh, L.M. Fabbri, J.W.H. Kocks, D.B. Price, Singapore, Singapore, p.A3314 P504 Preventing Clinically Important Deterioration with Umeclidinium/Vilanterol Versus Bronchodilator Monotherapy in Patients with Chronic Obstructive Pulmonary Disease Free of Inhaled Corticosteroids: A Prospective Analysis of the EMAX Trial/ C. Vogelmeier, F. Maltais, E. Kerwin, L. Bjermer, I. Naya, L. Tombs, I. Boucot, M.L. Watkins, D.A. Lipson, C. Compton, P. Jones, Marburg, Germany, p.A3315 P505 Effects of One-on-One Coaching in Improving Inhaler Technique and Symptoms Control of Chronic Obstructive Pulmonary Disease (COPD) Patients/ J.S. Kim, S. Choudhary, H. Li, N. Hashweh, S. Santosh, E. Charbek, St. Louis, MO, p.A3316 P506 Comparative Efficacy and Safety of Umeclidinium/Vilanterol, Umeclidinium and Salmeterol in Symptomatic Maintenance-Naïve and Maintenance-Treated Chronic Obstructive Pulmonary Disease: A Pre-Specified Secondary Analysis of the EMAX Trial/ L.H. Bjermer, E. Kerwin, F. Maltais, P. Jones, I. Boucot, L. Tombs, I. Naya, M. Watkins, D.A. Lipson, C. Compton, C. Vogelmeier, Lund, Sweden, p.A3317 P507 Safety and Efficacy of Revefenacin for Nebulization in Patients with Chronic Obstructive Pulmonary Disease Taking Concomitant LABA or ICS/LABA/ S. Sethi, J.F. Donohue, G.T. Ferguson, C.N. Barnes, G.D. Crater, Buffalo, NY, p.A3318 ATS 2019 • Dallas, TX MONDAY • MAY 20 161 MONDAY MORNING